The mevalonate pathway in breast cancer biology
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
Breast cancer affects one in eight women during their lifetime. Although diagnostic and therapeutic options have improved, recurrence, metastasis, and therapeutic resistance remain clinical challenges, which affect life quality and prognosis. The mevalonate pathway is an essential part of cellular homeostasis by providing a number of essential isoprenoid products including cholesterol. However, the disturbance of this pathway paralleled by increased bioavailability of its products and their direct involvement in several steps of tumorigenesis has highlighted the mevalonate pathway as a promising hub in cancer treatment. In this review, we will specifically discuss how the mevalonate pathway affects breast cancer biology in terms of supporting and modulating soluble and cellular factors and distinct steps of tumorigenesis. We will further summarize antitumor effects of the mevalonate pathway-inhibiting drugs, statins and amino-bisphosphonates, in breast cancer and discuss how they are used for future precision therapy.
Details
Original language | English |
---|---|
Article number | 215761 |
Pages (from-to) | 215761 |
Journal | Cancer letters |
Volume | 542 |
Publication status | Published - 28 Aug 2022 |
Peer-reviewed | Yes |
External IDs
Scopus | 85131410080 |
---|---|
unpaywall | 10.1016/j.canlet.2022.215761 |
WOS | 000810179200005 |
Mendeley | 7b50887c-fc7b-3e04-ac48-557f38d32d0e |
ORCID | /0000-0002-8691-8423/work/142236006 |
Keywords
Research priority areas of TU Dresden
DFG Classification of Subject Areas according to Review Boards
Subject groups, research areas, subject areas according to Destatis
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Biology, Breast Neoplasms/drug therapy, Cell Transformation, Neoplastic, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology, Mevalonic Acid/metabolism, Rho-GTPases, Amino-bisphosphonates, Breast cancer, Cholesterol, Statins